scispace - formally typeset
R

Rahul Jain

Researcher at National Institutes of Health

Publications -  119
Citations -  3726

Rahul Jain is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Catalysis & Alkylation. The author has an hindex of 30, co-authored 105 publications receiving 3207 citations. Previous affiliations of Rahul Jain include Tulane University & University of Louisville.

Papers
More filters
Journal ArticleDOI

Quinolines and structurally related heterocycles as antimalarials

TL;DR: This review provides a comprehensive literature compilation concerning the study of quinolines and also other heterocycles structurally similar to quinoline scaffold in the treatment of malaria.
Journal ArticleDOI

Antimalarials from nature

TL;DR: Recent advances in antimalarial drug discovery from natural sources are presented, including plant extracts, and compounds isolated from plants, bacteria, fungi and marine organisms, which offer new and novel scaffolds for development as antimalarials.
Journal ArticleDOI

Recent advances in new structural classes of anti-tuberculosis agents.

TL;DR: This review provides a comprehensive literature compilation on advances in the new structural classes of anti-TB analogs reported during the past five years and discusses and observations are concentrated on chemotherapeutic potential of alphabetically listed twenty-seven newStructural classes ofAnti-tuberculosis agents.
Journal ArticleDOI

Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.

TL;DR: A 3D-QSAR analysis of AQCH by its reaction with various aliphatic, aromatic, and heteroaromatic aldehydes led to the synthesis of 4-adamantan-1-yl-quinoline-2-carboxylic acid alkylidene hydrazides (Series 2), which have produced promising antimycobacterial activities.
Journal ArticleDOI

Ring-substituted quinolines as potential anti-tuberculosis agents.

TL;DR: In vitro antimycobacterial properties of ring-substituted quinolines constituting 56 analogues against drug-sensitive and drug-resistant M. tuberculosis H37Rv strains are reported, comparable to first line anti-tuberculosis drug, isoniazid.